Anna Cantarutti1, Luca Merlino2, Carlo Giaquinto3, Giovanni Corrao1. 1. Department of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, Laboratory of Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy. 2. Operative Unit of Territorial Health Services, Region of Lombardy, Milan, Italy. 3. Department of Women's and Children's Health, University of Padova, Padova, Italy.
Abstract
BACKGROUND: Untreated depression and antidepressant use during pregnancy may have negative consequences for births. There are still conflicting data on the potential harmful effects of prenatal antidepressant treatment on child health. OBJECTIVE: To investigate the relationship between the use of antidepressant medication during pregnancy and selected neonatal outcomes. METHODS: A population-based cohort study including 9825 deliveries exposed to an antidepressant between 9 months before last menstrual date through to delivery, from January 2005 to December 2010 in the Lombardy region of Italy, was conducted. We evaluated the prevalence ratio (PR) of low Apgar score, small for gestational age, intrauterine hypoxia and birth asphyxia, neonatal convulsion, and other respiratory conditions, among infants born to mothers exposed to an antidepressant during pregnancy using log-binomial regression analysis. Fine stratification was applied to the propensity score to account for all potential confounders. Sensitivity and subgroup analyses restricted to specific types of antidepressant, time of exposure, and women with vaginal deliveries and full-term births were also performed. RESULTS: A total of 33.4% of women filled at least one prescription during pregnancy. Compared to infants born to mothers with exposure to antidepressants only before pregnancy, those with exposure to antidepressants during pregnancy had an increased prevalence ratio of a low Apgar score (PR, 1.63, 95% CI, 1.01-2.61), intrauterine hypoxia and birth asphyxia (aPR, 1.37, 1.08-1.73), neonatal convulsion (aPR, 2.81, 1.07-7.36), and other respiratory condition (aPR, 1.24, 1.00-1.52). Results were similar in the sensitivity and subgroup analyses. CONCLUSIONS: Use of antidepressants during pregnancy may have an increased risk for several neonatal outcomes.
BACKGROUND: Untreated depression and antidepressant use during pregnancy may have negative consequences for births. There are still conflicting data on the potential harmful effects of prenatal antidepressant treatment on child health. OBJECTIVE: To investigate the relationship between the use of antidepressant medication during pregnancy and selected neonatal outcomes. METHODS: A population-based cohort study including 9825 deliveries exposed to an antidepressant between 9 months before last menstrual date through to delivery, from January 2005 to December 2010 in the Lombardy region of Italy, was conducted. We evaluated the prevalence ratio (PR) of low Apgar score, small for gestational age, intrauterine hypoxia and birth asphyxia, neonatal convulsion, and other respiratory conditions, among infants born to mothers exposed to an antidepressant during pregnancy using log-binomial regression analysis. Fine stratification was applied to the propensity score to account for all potential confounders. Sensitivity and subgroup analyses restricted to specific types of antidepressant, time of exposure, and women with vaginal deliveries and full-term births were also performed. RESULTS: A total of 33.4% of women filled at least one prescription during pregnancy. Compared to infants born to mothers with exposure to antidepressants only before pregnancy, those with exposure to antidepressants during pregnancy had an increased prevalence ratio of a low Apgar score (PR, 1.63, 95% CI, 1.01-2.61), intrauterine hypoxia and birth asphyxia (aPR, 1.37, 1.08-1.73), neonatal convulsion (aPR, 2.81, 1.07-7.36), and other respiratory condition (aPR, 1.24, 1.00-1.52). Results were similar in the sensitivity and subgroup analyses. CONCLUSIONS: Use of antidepressants during pregnancy may have an increased risk for several neonatal outcomes.
Authors: Kelsey Kathleen Wiggs; Ayehsa C Sujan; Martin E Rickert; Patrick D Quinn; Henrik Larsson; Paul Lichtenstein; Brian M D'Onofrio; A Sara Oberg Journal: Neurology Date: 2022-05-11 Impact factor: 11.800
Authors: Meera Viswanathan; Jennifer Cook Middleton; Alison M Stuebe; Nancy D Berkman; Alison N Goulding; Skyler McLaurin-Jiang; Andrea B Dotson; Manny Coker-Schwimmer; Claire Baker; Christiane E Voisin; Carla Bann; Bradley N Gaynes Journal: Psychiatr Res Clin Pract Date: 2021-05-04
Authors: Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; K C Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin Journal: J Clin Psychopharmacol Date: 2021 Jul-Aug 01 Impact factor: 3.153
Authors: Giovanni Corrao; Anna Cantarutti; Anna Locatelli; Gloria Porcu; Luca Merlino; Simona Carbone; Flavia Carle; Rinaldo Zanini Journal: Int J Environ Res Public Health Date: 2020-12-29 Impact factor: 3.390
Authors: Anna Cantarutti; Federico Rea; Matteo Franchi; Benedetta Beccalli; Anna Locatelli; Giovanni Corrao Journal: Int J Environ Res Public Health Date: 2021-11-30 Impact factor: 3.390
Authors: Giovanni Corrao; Federico Rea; Matteo Franchi; Benedetta Beccalli; Anna Locatelli; Anna Cantarutti Journal: Int J Environ Res Public Health Date: 2020-09-05 Impact factor: 3.390